Task Force on Implementation of HbA1c Standardization (Integrated Project) (TF-HbA1c)
Membership
| Name |
Position |
Country |
Term |
Time in Office |
| G. John |
Chair |
UK |
2nd |
2012 01 - 2014 12 |
| C. Weykamp |
Secretary |
NL |
2nd |
2012 01 - 2014 12 |
| L. Ji |
Member |
CN |
1st |
2012 01 - 2014 12 |
| R. Little |
Member |
US |
2nd |
2012 01 - 2014 12 |
| D. Sacks |
Member |
US |
2nd |
2012 01 - 2014 12 |
| I. Takai |
Member |
JP |
2nd |
2012 01 - 2014 12 |
| P. Gillery |
SD Liaison |
FR |
1st |
2011 01 - 2013 12 |
| R. Hinzmann |
EMD Liaison |
DE |
1st |
2012 01 - 2014 12 |
| G. Sypniewska |
CPD Liaison |
PL |
1st |
2011 01 - 2013 12 |
The Task Force for HbA1C (TF-HbA1c) is
an Integrated Project that involves input from a number of IFCC
functional units and also from clinical experts in the field of
diabetes.
Aim
To establish an interface between IFCC and its National /
Corporate Members and the clinical users of HbA1C to enable the
implementation of a scientifically sound reporting structure for
HbA1C standardised to the IFCC Reference Measurement Procedure.
Objectives
- To establish a small group of clinical and scientific experts
(maximum of 5); consider geographical balance.
- To act as an advisory board to the HbA1C Reference Laboratory
Network.
- Develop scientific links between National Networks.
- Advise manufacturers on delivery objectives.
- To establish links with professional bodies (scientific and
clinical) to enable transition of reportable HbA1C values.
- To help implement the consensus statement.
- Monitor the introduction of the Consensus statement
globally.
- Develop quality targets for the measurement of HbA1C, and on
basis of these targets, and in conjunction with professional
bodies, advise on the use of HbA1c for monitoring, diagnosis and
screening of diabetes and glucose intolerance
Delivery
- Develop educational material; consider translating into various
languages (e learning).
- Monitor developments through surveys.
- Attend international / National meetings to provide advice and
guidance based on best practice.
- Work with Manufacturers.
- Work with scientific bodies to establish workshops.
- Develop a website.
Accountability
The TF-HbA1C will report to the Executive Board through the
President.
List of addresses
Dr. Garry JOHN
Consultant Clinical Biochemist
and Head of Clinical Biochemistry
Norfolk and Norwich University Hospital
UK
Tel: +44 (0) 1603 286 933
Dr. Cas WEYKAMP
Queen Beatrix Hospital
Beatrixpark 1
7101 BN Winterswijk
The Netherlands
Tel.: + 31 543 544774
Dr. L. JI
China
Dr. Randie R. LITTLE
University of Missouri School of Medicine
Departments of Pathology and Anatomical
Sciences and Child Health
M767, 1 Hospital Dr.
Columbia, MO 65212
USA
Tel.: +1 573-882-1257
Dr. David B. SACKS
Associate Professor of Pathology
Harvard Medical School
Brigham and Women`s Hospital
Thorn 530
75 Francis St
Boston, MA 02115
USA
Prof. Izumi TAKEI
Director for diabetes and endocrinology
Ichikawa General Hospital
Tokyo Dental College
5-11-13,Sugano,
Ichikawa-city, Chiba 272-8513
Japan
Phone:+81-47-322-0151
Fax:+81-47-325-4456